Dr. Curtis has received consultant/advisory board and/or speaking fees from Procter & Gamble, Amgen, Centocor, Eli Lilly, and Merck (less than $10,000 each), and from UCB, Roche, Consortium of Rheumatology Researchers of North America, and Novartis (more than $10,000 each), and research grants from Merck, Procter & Gamble, Eli Lilly, Roche, Centocor, Consortium of Rheumatology Researchers of North America, Amgen, and Novartis.
Physician preference motivates the use of anti–tumor necrosis factor therapy independent of clinical disease activity
Article first published online: 28 DEC 2009
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 1, pages 101–107, 15 January 2010
How to Cite
Curtis, J. R., Chen, L., Harrold, L. R., Narongroeknawin, P., Reed, G. and Solomon, D. H. (2010), Physician preference motivates the use of anti–tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res, 62: 101–107. doi: 10.1002/acr.20020
- Issue published online: 28 DEC 2009
- Article first published online: 28 DEC 2009
- Manuscript Accepted: 6 JUL 2009
- Manuscript Received: 12 MAR 2009
- Doris Duke Charitable Foundation
- NIH. Grant Numbers: AR-053351, AR-053856, grants AR-047782, AG-027066
- Agency for Healthcare Research and Quality
- Arthritis Foundation
- 4Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum 2006; 54: 3390–8., , , , .
- 17Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat 2007; 3: Article 14., .